Dmytro Kharkov

NeoGenomics integrates genomic testing into Epic workflows as stock falls 4.8%

NeoGenomics integrates genomic testing into Epic workflows as stock falls 4.8%
NeoGenomics stock falls 4.8% today

NeoGenomics has joined forces with Epic Aura to integrate genomic testing into Epic’s workflows, aiming to streamline processes and minimize errors for healthcare providers. Shares are down 4.8% on the day at $16.22.

Highlights

  • NeoGenomics formed a partnership with Epic Aura to embed genomic testing in Epic workflows, aiming to reduce manual tasks and errors.
  • Shares of NeoGenomics are down 4.8% on the day at $16.22.
  • 33 of 48 analysts rate NeoGenomics stock a buy, with a median price target of $20, about 23.3% above current levels.

NeoGenomics announced it has partnered with Epic Aura to integrate genomic testing capabilities directly into Epic workflows. The company said the integration aims to eliminate unnecessary manual processes and reduce errors caused by transcription and data re-entry. The update was published through NeoGenomics' own account.

Gap lower as near-term price diverges from bullish structure

Shares of NeoGenomics opened with a gap down from $17.04 to $16.63. Price is tracking below the MA-20 and MA-50 but remains above the MA-200, reflecting a split daily structure. The nearest resistance is the prior weekly low at $16.42. Overall, the recent move is running against the broader bullish chart structure.

Upside probability holds as weekly outlook remains constructive

Traders should watch for a close above $16.42 to confirm buyers are willing to follow through. The session began with a gap lower from $17.04 to $16.63. Even so, over the coming trading week the upside probability stands at 63%, with downside at 37%, and the expected range is $15.79 to $16.64. A drop below $12.63 would show the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.

Previously it was reported that NeoGenomics expanded its partnership with Indica Labs to advance its digital pathology capabilities. The new collaboration with Epic Aura represents a further evolution of NeoGenomics' technology ecosystem, and traders should monitor whether sustained price action above $16.42 can reestablish the stock’s bullish momentum.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.